The STARBURST study (ClinicalTrials.gov Identifier: NCT05563272) is a prospective, open label Phase II "basket" study to investigate CAIX expression in pat...
QIAGEN N.V. announced a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecure...
PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the researc...
This three-year collaboration aims to validate genetic drug targets and progress therapeutic molecules into clinical development. The joint resea...
Under the terms of the agreement, the two companies aim to develop multiple targeted protein degraders by combining Cullgen's proprietary uSMITE™ tar...
-Swiss American CDMO and BioNTX have partnered to host the inaugural Biotechnology and Healthcare Industry Alliance of North Texas (BHIANT) launch meeting ...
Future Fields, a pioneering biotechnology company that has built the world’s first synthetic biology system to use fruit flies for recombinant protei...
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development wi...
SomaLogic, Inc., a leader in proteomics technology, announced today their collaboration with Citogen, the Longwood Group’s customer services and supp...
Salipro Biotech AB, a pioneering biotech company focusing on challenging drug targets for the discovery of next-generation therapeutics, is delighted to an...
Annexus Health, Inc., the leading healthcare technology company that is revolutionizing the patient access journey through its innovative solutions, today ...
Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture ther...
BetaLife wins top prize with its potential to provide regenerative medicines to patients with severe diabetes in Southeast Asia. Cytiva’s BioChall...
Agilent Technologies Inc. (NYSE: A) announced today a highly-anticipated, complete workflow solution for targeted per- and polyfluoroalkyl substances (PFAS...
© 2025 Biopharma Boardroom. All Rights Reserved.
